EU Approves First-Line Use of AstraZeneca and Daiichi Sankyo's Enhertu

Enhertu, jointly developed by AstraZeneca and Daiichi Sankyo, has received approval from the European Union for use as a first-line treatment in certain patients with HER2-positive breast cancer. This approval covers the drug's use in combination with pertuzumab, offering a new treatment option in advanced stages of the disease. The European Commission's decision is based on clinical data demonstrating Enhertu's efficacy in patients who have not previously received treatment or have had limited prior therapy. The approval is considered a significant development, particularly for patients with metastatic breast cancer and HER2-positive tumors. This decision expands the drug's accessibility across Europe and marks another success for the oncology collaboration between AstraZeneca and Daiichi Sankyo. Enhertu had previously received approvals for various breast cancer subtypes; however, this new indication strengthens its position in the first-line treatment setting. Experts note that this approval has the potential to extend patient survival and may offer a more effective option compared to current standard treatments. However, the drug's cost and reimbursement conditions may vary by country, and health authorities will continue their assessments. This is not investment advice.